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Atrial fibrillation is a frequent cause of stroke; in the elderly, more than 20% of strokes are attributed to this common arrhythmia. Antic-
oagulation with warfarin reduces the risk of stroke by 60%; however, a large proportion of patients with atrial fibrillation do not receive
this treatment because of relative/absolute contraindications. Moreover, patients often discontinue warfarin for a variety of reasons and
chronic warfarin administration rates remain suboptimal. Although the compliance with anticoagulation may improve with novel anticoagu-
lants and bleeding risk can be somewhat reduced when compared with warfarin, there is still a progressive increase in bleeding complications
over time. Accordingly, new approaches for stroke prevention in these patients are being explored and tested. In transoesophageal echo-
cardiographic (TEE) studies, more than 90% of thrombi were found in the left atrial appendage (LAA) in non-valvular atrial fibrillation, and
transcatheter LAA closure is developed and examined as a novel approach to reduce the risk of stroke in these patients. The PROTECT-AF
study provides first evidence from a randomized clinical trial that a strategy of LAA occlusion using the Watchman device can be non-inferior
to anticoagulation with warfarin for a combined endpoint in patients with non-valvular atrial fibrillation (mean CHADS2 score 1.8). In suc-
cessfully occluded patients fulfilling TEE criteria (86%), warfarin was stopped after 45 days, followed by aspirin and clopidogrel for 6 months
after randomization and subsequently aspirin. The PREVAIL trial is further evaluating this concept. Limited data are available for another LAA
occlusion system, the Amplatzer Cardiac Plug (ACP) device, for which the ACP trial has been initiated. Left atrial appendage occlusion needs
to be performed with meticulous care by experienced operators because periprocedural complications such as pericardial effusion or stroke
have been documented. With increased operator experience and technical improvements of the device, these complications can be
minimized.
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Introduction
Stroke remains a main cause of morbidity and mortality from car-
diovascular disease with an annual incidence of } 795 000 patients
with a new or recurrent stroke and an estimated prevalence of
7 million patients in the USA.1 In high-income countries, 80%
of strokes are caused by focal cerebral ischaemia due to arterial
occlusion, and the remaining 20% are caused by cerebral hae-
morrhages.1 The incidence of stroke increased markedly with ad-
vancing age; the percentage of strokes attributable to atrial
fibrillation increase steeply from 1.5% at 50–59 years of age
to more than 20% at 80–89 years of age, making atrial fibrillation
a primary risk factor of stroke in these patients.1 Moreover, strokes
related to atrial fibrillation have been observed to be associated
with a higher mortality and morbidity when compared with
non-atrial fibrillation strokes, emphasizing the need for more
effective stroke prevention in these patients.2
Stroke prevention in patients with atrial fibrillation has largely
been based on the use of anticoagulation with warfarin, which
reduces the risk of stroke by 60%,3 and more recently on the
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use of novel anticoagulants in some patients, such as the direct
thrombin inhibitor dabigatran.4 Therapy with warfarin or the
novel oral anticoagulants, e.g. the direct thrombin inhibitor dabiga-
tran or the selective factor Xa inhibitors apixaban and rivaroxaban,
comes with a significant life-time risk of major bleedings ranging
from 1.4 to .3% per year in clinical trials,4 –8 which have excluded
patients with a high risk of bleeding. A recent analysis of the RE-LY
trial has suggested that in patients with atrial fibrillation at risk for
stroke, the lower and the higher dose of dabigatran compared with
warfarin had a lower risk of both intracranial and extracranial
bleeding in patients aged ,75 years. In those aged ≥75 years,
intracranial bleeding risk is lower, but extracranial bleeding risk is
similar or higher with both doses of dabigatran compared with
warfarin.8 The cumulative incidence of major haemorrhage for
patients ≥80 years of age has been estimated to be as high as
13.1 per 100 person-years, and these patients are not frequently
enrolled in randomized clinical trials.9
A significant proportion of patients with atrial fibrillation, ranging
from 30 to 50%, do not receive anticoagulation due to relative or
absolute contraindications or due to patient- and/or physician-
pertinent barriers limiting the use of anticoagulation in clinical prac-
tice, including the perceived risk or fear of treatment-induced
bleedings.10,11 Moreover, the persistent use of anticoagulation
with warfarin prescribed for secondary prevention after stroke
was observed to decline to 45% after 2 years in a recent analysis
from a large Swedish stroke registry (Figure 1).12
For these reasons, device-based therapies are currently being
developed for stroke prevention in non-valvular atrial fibrillation
and potentially offer an alternative approach for stroke prevention
in these patients which will be the focus of the present review
article.
Left atrial appendage closure: the
rationale
The trabecular left atrial appendage (LAA) is the remnant of the
original embryonic left atrium and develops during the third
week of gestation, whereas the main smooth-walled left atrial
cavity develops later.13 The LAA has been the site in the left
atrium where more than 90% of thrombi were detected in patients
with non-valvular atrial fibrillation in transoesophageal studies.14
The LAA has therefore been considered by some our ‘most
lethal human attachment’.15
The LAA is actively contracting and has a characteristic pattern
of emptying in sinus rhythm, which can be detected by both trans-
oesophageal echocardiography (TEE) and cardiac magnetic reson-
ance imaging studies.16
In patients with atrial fibrillation, however, blood flow velocity in
the LAA frequently decreases, resulting in stasis and increasing the
probability of thrombus formation.16,17 Thrombi have been
detected by TEE in 15% of patients with atrial fibrillation.14,18
Of note, in immunohistochemical studies, immunoreactive von
Willebrand factor, a platelet adhesion molecule, was increased in
overloaded human LAAs, which likely can predispose to thrombus
formation,19 in addition to the anatomical and structural factors
favouring thrombus formation in the LAA. In the SPAF III (Stroke
Prevention in Atrial Fibrillation III) trial including patients with non-
valvular atrial fibrillation, TEE was performed in 786 study partici-
pants, and thrombi detected in the LAA as well as a reduced LAA
peak flow velocity were identified as independent predictors of an
increased thrombo-embolic risk.20 In the same study, detection of
complex aortic plaques by TEE was also associated with an
increased thrombo-embolic risk, indicating that causes of stroke
are likely multifactorial in elderly patients with atrial fibrillation
and that LAA closure is unlikely to prevent all ischaemic strokes
in these patients.20 The frequent detection of left atrial thrombi
in the LAA as well as the observed association of LAA thrombi
with an increased thrombo-embolic risk do not yet, however,
prove a causal relationship between LAA thrombi and stroke.
The concept that exclusion of LAA from the circulation reduces
the risk of stroke in patients with non-valvular atrial fibrillation is
therefore being examined in clinical studies as a potential novel
approach to prevent cardioembolic strokes in these patients as
described in detail below.
Development of transcatheter left
atrial appendage occlusion
The first technology developed for percutaneous transcatheter
LAA occlusion was the Percutaneous Left Atrial Appendage Trans-
catheter Occlusion (PLAATO) device, a self-expanding nitinol cage
covered with a polymeric membrane.21 The device was manufac-
tured with anchors to prevent embolization, and it was made in
a variety of sizes.21 Ostermayer et al. reported the early experi-
ence with this device in two prospective, multicentre observational
studies, where a successful device implantation was achieved in 108
out of 111 patients. This report suggested that transcatheter LAA
occlusion is feasible and can be performed with an acceptable risk
in patients with atrial fibrillation and a contraindication for anticoa-
gulation therapy.22 One patient (0.9%) experienced two major
adverse events within 30 days (i.e. need for cardiovascular
surgery and in-hospital neurological death, likely due to cerebral
haemorrhage after anticoagulation had been instituted for
Figure 1 The analysis of a recent study examining the persist-
ent use of a prescribed anticoagulation in a cohort of stroke sur-
vivors (21 077 survivors) is shown, indicating that the persistent
use of anticoagulation with warfarin declined to 45% after 2
years (adopted and modified from Glader et al.12).
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a thrombosis). Three other patients underwent in-hospital peri-
cardiocentesis due to a haemopericardium, of which two patients
were the first patients at a new site in which pericardial haemor-
rhage occurred during the attempt to enter the LAA after trans-
septal puncture.22 No device migration or mobile thrombus was
noted on the device at 1 and 6 months after device implantation.22
Two patients experienced stroke during an average follow-up of
9.8 months, i.e. the annual stroke rate was 2.2%.22 The estimated
annual stroke rate for these patients was 6.3% (using the
CHADS2 score), assuming that patients were taking aspirin.
22
Bayard et al.23 described the experience of the following
European PLAATO study including 180 elderly patients with
atrial fibrillation and contraindications for anticoagulation. Left
atrial appendage occlusion was successful in 162 of the 180
patients (90%).23 Two patients (1.1%) died within 24 h. In one
patient (82-year-old), the cause of death was thought to be exar-
cerbation of chronic heart failure secondary to severe coronary
disease following anaesthesia. The second patient (74-year-old)
was operated for pericardial tamponade after attempted device
implantation and died due to haemorrhagic shock after rupture
of iliac artery, when removing the device, that had embolized
during resuscitation, was attempted with a snare catheter.23 Includ-
ing the above event, there were six patients (3.3%) with pericardial
tamponade that had to be drained surgically in two patients.23 The
reported incidence of strokes (2.3%/year) in patients with the
PLAATO device and aspirin was lower when compared with
the expected annual stroke risk according to the CHADS2 score
(6.6%/year) in a mean follow-up of 9.6 months.23 This study was
halted prematurely during the follow-up phase for financial consid-
erations. Block et al.24 reported the long-term experience in the
USA and Canada from a mean follow-up of 3.75 years in 64
patients of the PLAATO study, suggesting a lower annual stroke
rate compared with that predicted from the CHADS2 score. Al-
though the clinical development programme for this device has
been halted, there are lessons that can be learned. There were
certain limitations of the PLAATO device, e.g. it was rather rigid
and required therefore 20–50% oversizing when compared with
the LAA orifice to achieve a stable position. In contrast, more
recent LAA occlusion devices, i.e. the Watchman device and the
Amplatzer Cardiac Plug (ACP) device, are more flexible and
need only 10–20% oversizing to achieve a stable position in the
LAA. That is important since the LAA has typically an oval
orifice.25– 27 Furthermore, the flatter shape of the more recent
devices when compared with the PLAATO device allows also
for occlusion of LAAs that have a short proximal portion and an
early separation into lobes, which could not be completely
occluded by the PLAATO device due to the necessity of a
deeper implantation. Notably, in 80%, the LAA is multilobu-
lated.26 Indeed, the LAA has a very individual anatomy, almost
like a finger print, with a different number of lobes (1–4), substan-
tial differences in length and orifice size, that makes a flatter LAA
occlusion device more appropriate for occlusion of a significant
proportion of LAAs (Figure 2).25 –27
The feasibility and early experience using the WATCHMAN Left
Atrial Appendage System (Atritech Inc., Plymouth, MN, USA), a
self-expanding nitinol device for percutaneous implantation to
seal the LAA, was reported in 2007.28 In this feasibility study, com-
plete LAA sealing was observed in 54 of 58 patients (93%) by TEE
at 45 days, and no strokes were reported during a mean follow-up
of 740 days.28 Importantly, the Watchman device is the first LAA
Figure 2 Anatomical specimens showing the variable anatomy of the left atrial appendage, i.e. a single-lobed (A) left atrial appendage and a
bi-lobed left atrial appendage (B), the most frequent variant of left atrial appendage anatomy. Both specimens illustrate the difference between
the trabecular left atrial appendage and the smooth-walled left atrial cavity, which have diverse embryonic origins. The echocardiographic orifice
(Oe) is often larger than the anatomic orifice (Oa) (adapted and modified from Veinot et al.26 and Agmon et al.38 LA, left atrium; LSPV, left
superior pulmonary vein.
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occlusion device that has been evaluated in a prospective, con-
trolled, randomized trial, the Watchman Left Atrial Appendage
System for Embolic Protection in Patients with Atrial Fibrillation
(PROTECT-AF) clinical trial.29
In this multicentre non-inferiority trial performed in 59 centres
in the USA and Europe comparing long-term treatment with war-
farin vs. LAA occlusion with the Watchman device, patients were
eligible if they had non-valvular atrial fibrillation and at least one of
the following: previous stroke or transient ischaemic attack, con-
gestive heart failure, diabetes, hypertension, or age .75 years,
i.e. a CHADS2 score ≥1. Seven hundred and seven eligible patients
were randomly assigned in a 2:1 ratio to percutaneous closure of
the LAA and subsequent discontinuation of warfarin (n ¼ 463) or
long-term warfarin therapy with INR between 2.0 and 3.0 (control;
n ¼ 244). In patients randomized to the percutaneous device
closure arm, the device was successfully implanted in 408 of 463
patients (88%) and warfarin therapy was terminated after 45
days in most of these patients [349 of 408 patients (86%)
meeting TEE criteria of either complete closure of LAA or
minimal residual peri-device flow; jet ,5 mm in width] and
these patients were then treated with aspirin and clopidogrel for
6 months after randomization, followed by long-term aspirin
monotherapy.29 The trial results demonstrated that the probability
of non-inferiority of the device was greater than 99.9% with regard
to the primary efficacy endpoint (occurrence of ischaemic or
haemorrhagic stroke, cardiovascular or unexplained death, or sys-
temic emboli within up to 3 years) based on an analysis of 1065
patient-years of follow-up. Patients receiving the device had
fewer haemorrhagic strokes than the controls. In a safety analysis
of the primary endpoint including only patients of the intervention
group who were successfully treated and who discontinued war-
farin therapy, the primary efficacy event rate was 1.9 per 100
patient-years when compared with 4.6 per 100 patient-years in
control patients who received long-term warfarin.29
The primary safety endpoint consisting of events related to
excessive bleeding (e.g. intracranial or gastrointestinal bleeding)
or procedure-related complications (serious pericardial effusion,
device embolization, or procedure-related stroke) was signifi-
cantly greater in the device group (7.4 vs. 4.4 per 100 patient-
years).29 The most frequent primary safety event in the
intervention group was serious pericardial effusion (defined as
the need for percutaneous or surgical drainage), which occurred
in 22 (4.8%) patients. Fifteen of these patients were treated with
pericardiocentesis and seven underwent surgical intervention;
there was no fatality due to pericardial effusion.29 As described
below, pericardial effusion rates declined with increasing oper-
ator experience. Device embolization occurred in three patients;
one was noted during the procedure and two were observed by
TEE on Day 45 of follow-up; one device was removed using a
vascular snare; the other two patients underwent surgery.
There were five patients with a procedure-related stroke, of
which three had no long-term residual deficit, whereas two
patients were discharged to nursing homes and subsequently
died. After the periprocedural timeframe, ischaemic stroke
occurred in nine patients in the intervention group (1.3
events/100 patient-years) compared with six patients in the
control group (1.6 events/100 patient-years).29
A recent analysis of the non-randomized Continued Access
Protocol (CAP) registry including 460 subsequent patients after
the PROTECT-AF study had been completed, documented a sig-
nificant improvement in the safety of the Watchman LAA
closure, a result of increased experience of the operators (all
operators had participated in the PROTECT-AF trial) as well as
technical improvements in the device.30 In this group, serious peri-
procedural pericardial effusion were observed in 10 patients (2.2%)
and no procedure-related strokes were reported. These findings
clearly suggest in line with the experience with the PLAATO
device that increasing experience of the operators reduces the
risk of periprocedural complications. In addition, another recent
analysis from the PROTECT-AF study has shown that the small iat-
rogenic atrial septal defects (ASDs) that are frequently observed
after transseptal procedure with a large-diameter transseptal
sheath of 12 F have a very high spontaneous closure rate and are
not associated with an increased rate of stroke or systemic embol-
ization during long-term follow-up.31
A second prospective, randomized trial using the Watchman
device, i.e. the PREVAIL trial, is currently under way and will
provide further information for the LAA occlusion procedure.
Another device designed for LAA occlusion is the ACP, which is
CE marked in Europe and consists of a body for device fixation in
the LAA and a disc for sealing of the LAA from the circulation
(Figure 3C). An investigator-initiated retrospective data collection
to evaluate the procedural feasibility and safety up to 24 h after
implantation of the ACP device has recently been reported32 as
well as a small registry from the Asia-Pacific experience.33 Park
et al.32 reported that LAA occlusion using the ACP device was suc-
cessfully performed in 132 of 137 patients (96%). There were
serious complications in 10 patients (7%), of which 3 patients
had an ischaemic stroke, 2 patients experienced device emboliza-
tion (which could be percutaneously recaptured), and 5 patients
had a clinically significant pericardial effusion.32 As a note of
caution, it should be added that these data are self-reported and
non-adjudicated. A pivotal trial for the ACP device, the ACP trial
(http://www.acptrial.com), with a similar study design as the
PROTECT-AF trial has been initiated and is recruiting patients.
Safeguarding the procedure
In Europe, the Watchman device and the ACP are at present
already widely used, in particular in patients with non-valvular
atrial fibrillation who have an absolute or relative contraindica-
tion to anticoagulation and a relevant risk of an ischaemic
stroke (i.e. CHADS2 score .1). As described above, two pro-
spective, randomized trials are currently recruiting patients, i.e.
the PREVAIL and ACP trials, that will provide important data
on the efficacy and safety of LAA occlusion in atrial fibrillation
using the Watchman or ACP device. The above observations
clearly suggest that LAA occlusion needs to be performed by
experienced operators.
The observation that operator experience reduces the rates of
periprocedural complications suggests that in centres where the
technique is started, this needs to be done together with an experi-
enced operator. Moreover, the follow-up of patients is very import-
ant to optimize the procedure. For both devices, there has been the
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observation that in a small percentage of patients, thrombus may
form on the device in the first weeks/months after implantation,
suggesting that TEE follow-up after the procedure is important to
detect this abnormality. In the majority of patients, the detected
thrombus disappears after short-term anticoagulation.30,34,35 In a
follow-up report for the Watchman device, a device-associated
thrombus was described in 20 of 478 successfully implanted patients
(4.2%).30 Of these patients, 17 patients were either asymptomatic or
endothelialized with anticoagulation. This suggests a device-related
thrombus-associated annualized stroke rate of 0.3% per 100 patient-
years.30 The experience from histological analyses of the Watchman
device suggests that in the long term, there is device endothelization
which should minimize the risk of device-related thrombus
formation.36
Furthermore, in the PROTECT-AF study, all patients were
treated for 45 days after device implantation with warfarin. There-
fore, the safety and efficacy of LAA closure without short-term
warfarin treatment is not known and more experience and data
are needed in patients with an absolute contraindication for war-
farin therapy.
For the ACP device, less data on periprocedural complications
are available.32 The Amplatzer PFO and ASD devices have a very
low risk of device-related thrombus formation;37 however, these
devices are frequently implanted in patients without atrial fibrilla-
tion. For the ACP device, thrombus formation on the device has
been reported in some individual cases,34,35 which could be
resolved by short-term anticoagulation, suggesting that the TEE
follow-up is important for this device as well. More follow-up
data are needed for this device, both from registries and clinical
trials such as the ACP trial.
Conclusions and perspective
As described above, the available data suggest that LAA occlusion
reduces the risk of stroke in patients with non-valvular atrial fibril-
lation, and the PROTECT-AF study provides the first evidence
from a randomized clinical trial that this therapeutic device inter-
vention (as performed with warfarin for 45 days in successfully
occluded patients fulfilling TEE criteria; aspirin and clopidogrel
for 6 months followed by aspirin) is non-inferior to anticoagulation
Figure 3 Devices for percutaneous transcatheter left atrial appendage closure that have been examined in clinical studies. (A) The PLAATOw
device (ev3 Endovascular, Inc., North Plymouth, MN, USA) was the first transcatheter left atrial appendage occlusion device implanted percu-
taneously in patients with atrial fibrillation. (B) The WATCHMANw Left Atrial Appendage System (Atritech Inc.) is the first left atrial appendage
occlusion device examined in a prospective, randomized clinical trial vs. anticoagulation with warfarin. The WATCHMAN Left Atrial Appendage
System consists of a parachute-shaped device with a self-expanding nitinol frame structure with a permeable polyester membrane over the atrial
side and mid-perimeter fixation barbs to secure it in the left atrial appendage. (C) The AMPLATZERw Cardiac Plug device (AGA Medical Cor-
poration, Golden Valley, MN, USA) consists of two bodies, i.e. a distal anchoring lobe and a proximal sealing disc linked via a flexible central
waist. On the right panel, three-dimensional transoesophageal images are shown before and after left atrial appendage occlusion. The 3DTEE
images were obtained at University Hospital Zurich (courtesy of Dr David Hu¨rlimann).
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with warfarin using the combined endpoint.29 The rate of ischae-
mic strokes was numerically higher in the device intervention
group, which could be attributed to five periprocedural strokes
(mainly air embolism). The recent CAP registry suggests that the
complication rates during LAA occlusion likely improve with
increasing operator experience, since no procedure-related
strokes were reported in 460 consecutive patients.30
If these findings are substantiated by further randomized trials,
one may speculate that the benefit of a device-based approach
could be more pronounced in clinical practice than that observed
in clinical trials, given the observation that even in patients after an
ischaemic stroke, the persistent use of a prescribed anticoagulation
therapy with warfarin in clinical practice after 2 years was lower
than 50%.12 However, the compliance with anticoagulation may
also improve with the novel anticoagulants. Therefore, more
detailed information on the persistent use of the novel anticoagu-
lants as well as on the complication rate of LAA occlusion when it
is more widely used in clinical practice will be of interest in this
respect.
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Thrombus formation 10 years after placement of an atrial septal secundum
defect closure device
Maria Bonou, Konstantinos M. Lampropoulos*, and John Barbetseas
Department of Cardiology, Polyclinic General Hospital, 3 Pireos Ave., Omonia Sq., 105 52 Athens, Greece
* Corresponding author. Tel/Fax: +30 2108950863, Email: konlampropoulos@yahoo.gr
A 65-year-old female patient with a 24 mm atrial
septal secundum defect underwent successful
percutaneous closure of the defect 10 years
earlier using a 38 mm StarFlex device; NMT
Medical, Boston, MA, USA. The patient was
undergoing follow-up annually with no abnormal
findings at echocardiography or other
complications.
At her recent echocardiography evaluation,
two-dimensional (2D) study demonstrated a
mass 2 × 2 cm (arrows) in the right atrium at
the posterior portion of the device (Panel A).
The transoesophageal echocardiography and
three-dimensional transthorasic echocardiography
(3D) images of the mass are shown in Panels B and
C, respectively. A cardiac magnetic resonance
imaging followed the echocardiography evaluation
(Panel D) and confirmed the diagnosis of the mass
within the right atrium, which was consistent with
a large thrombus attached to the posterior
portion of the closure device. This is the first case reported in the literature of thrombus formation on a closure device 10 years
after the intervention, probably due to incomplete endothelialization of the device. This case demonstrated the need for continuous
follow-up of patients after device implantation.
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